Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS coverage for kidney transplant diagnostics. Issues related to health insurance coverage and regulation of FDA cleared biomarkers to predict preeclampsia.
Duration: November 1, 2019
to
present
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations
Spending: about $860,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
John Kevin Brennan Chief of Staff, Rep. Rosa DeLauro (D-CT); Director, Rep. Sherrod Brown (D-OH); Legislative Assistant, Rep. Tom Foglietta (D-PA)
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific Inc. , earning $40,000. The report was filed on April 23.
Original Filing: 301576812.xml
Lobbying Issues
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS coverage for kidney transplant diagnostics. Issues related to health insurance coverage and regulation of FDA cleared biomarkers to predict preeclampsia.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific Inc. , earning $40,000. The report was filed on Jan. 5.
Original Filing: 301522007.xml
Lobbying Issues
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS coverage for kidney transplant diagnostics.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific Inc. , earning $40,000. The report was filed on Oct. 19, 2023.
Original Filing: 301506210.xml
Lobbying Issues
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS coverage for kidney transplant diagnostics.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific Inc. , earning $40,000. The report was filed on July 11, 2023.
Original Filing: 301474459.xml
Lobbying Issues
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS coverage for kidney transplant diagnostics.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific Inc. , earning $40,000. The report was filed on April 18, 2023.
Original Filing: 301454077.xml
Lobbying Issues
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage for small cell lung cancer genetic test.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific Inc. , earning $40,000. The report was filed on Jan. 19, 2023.
Original Filing: 301434027.xml
Lobbying Issues
H.R. 3932 / S. 2076, The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4114 / S. 701, Allergy Testing Access Act of 2021. Medicare coverage for small cell lung cancer genetic test.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific Inc. , earning $40,000. The report was filed on Oct. 11, 2022.
Original Filing: 301402427.xml
Lobbying Issues
H.R. 3932 / S. 2076, The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4114 / S. 701, Allergy Testing Access Act of 2021; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific Inc. , earning $40,000. The report was filed on July 12, 2022.
Original Filing: 301379261.xml
Lobbying Issues
H.R. 3932 / S. 2076, The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4114 / S. 701, Allergy Testing Access Act of 2021; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific Inc. , earning $40,000. The report was filed on April 18, 2022.
Original Filing: 301359152.xml
Lobbying Issues
H.R. 3932 / S. 2076, The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4114 / S. 701, Allergy Testing Access Act of 2021; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific Inc. , earning $50,000. The report was filed on Jan. 18, 2022.
Original Filing: 301325386.xml
Lobbying Issues
Legislation to establish biopharmaceutical worker training program and issues regarding drug shortages. The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4114 / S. 701, Allergy Testing Access Act of 2021; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics. H.R. 5993, MEDS in America Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific Inc. (FKA Thermo Fisher Scientific) , earning $50,000. The report was filed on Oct. 15, 2021.
Original Filing: 301300122.xml
Lobbying Issues
Legislation to establish biopharmaceutical worker training program and issues regarding drug shortages. The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4114 / S. 701, Allergy Testing Access Act of 2021; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific , earning $60,000. The report was filed on July 19, 2021.
Original Filing: 301283028.xml
Lobbying Issues
Legislation to establish biopharmaceutical worker training program and issues regarding drug shortages. The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4114 / S. 701, Allergy Testing Access Act of 2021; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific , earning $60,000. The report was filed on April 16, 2021.
Original Filing: 301254873.xml
Lobbying Issues
Legislation to establish biopharmaceutical worker training program and issues regarding drug shortages. The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 701, Allergy Testing Access Act of 2021; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific , earning $60,000. The report was filed on Jan. 19, 2021.
Original Filing: 301236915.xml
Lobbying Issues
Issues regarding drug shortages; issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2020 Labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific , earning $60,000. The report was filed on Oct. 13, 2020.
Original Filing: 301209075.xml
Lobbying Issues
Issues regarding drug shortages; issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2020 Labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific , earning $60,000. The report was filed on July 7, 2020.
Original Filing: 301185747.xml
Lobbying Issues
Issues regarding drug shortages; issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2020 Labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific , earning $60,000. The report was filed on April 14, 2020.
Original Filing: 301166599.xml
Lobbying Issues
Issues regarding drug shortages; issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2020 Labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, BLUEBIRD STRATEGIES lobbied for Thermo Fisher Scientific , earning $40,000. The report was filed on Jan. 16, 2020.
Original Filing: 301107904.xml
Lobbying Issues
Issues regarding drug shortages; issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2020 Labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
BLUEBIRD STRATEGIES filed a lobbying registration on Dec. 4, 2019 to represent Thermo Fisher Scientific, effective Nov. 1, 2019.
Original Filing: 301091930.xml
Issue(s) they said they’d lobby about: Issues regarding drug shortages; FY2019 Labor HHS appropriations legislation; issues related to sepsis treatment and antibiotic stewardship; asthma policies and diagnostic allergy test coverage. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...